Latest news on FDA’s second look at Amylyx; Unpacking Parkinson’s R&D; Fiona Marshall takes over NIBR from Jay Bradner; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
This is going to be a long weekend for us at Endpoints, thanks to Labor Day in the US, and it’s much needed. September is shaping up to be a busy month, with biopharma seemingly coming back from the summer and events kicking into gear. If you have any news to share, we always appreciate some lead time. For the daily readers — see you on Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.